A Study of the Effect of Cyclosporine on Fevipiprant Pharmacokinetics and its Absolute Bioavailability Using an Intravenous Microdose Approach.
ATP Binding Cassette Transporter, Subfamily B
/ metabolism
Administration, Intravenous
Administration, Oral
Adolescent
Adult
Area Under Curve
Biological Availability
Cross-Over Studies
Cyclosporine
/ administration & dosage
Drug Interactions
Female
Healthy Volunteers
Humans
Indoleacetic Acids
/ administration & dosage
Male
Middle Aged
Pyridines
/ administration & dosage
Solute Carrier Organic Anion Transporter Family Member 1B3
/ metabolism
Young Adult
Journal
Drug metabolism and disposition: the biological fate of chemicals
ISSN: 1521-009X
Titre abrégé: Drug Metab Dispos
Pays: United States
ID NLM: 9421550
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
04
02
2020
accepted:
17
07
2020
pubmed:
3
8
2020
medline:
9
9
2021
entrez:
3
8
2020
Statut:
ppublish
Résumé
This drug-drug interaction study determined the effect of cyclosporine, an inhibitor of organic anion transporting polypeptide (OATP) 1B3 and P-gp, on the pharmacokinetics (PK) of fevipiprant, an oral, highly selective, competitive antagonist of the prostaglandin D
Identifiants
pubmed: 32739890
pii: dmd.120.090852
doi: 10.1124/dmd.120.090852
doi:
Substances chimiques
ABCB1 protein, human
0
ATP Binding Cassette Transporter, Subfamily B
0
Indoleacetic Acids
0
Pyridines
0
SLCO1B3 protein, human
0
Solute Carrier Organic Anion Transporter Family Member 1B3
0
fevipiprant
2PEX5N7DQ4
Cyclosporine
83HN0GTJ6D
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
917-924Informations de copyright
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.